Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 256 articles:
HTML format



Single Articles


    November 2022
  1. BUKAVINA L, Luckenbaugh AN, Hofman MS, Hope T, et al
    Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.
    Eur Urol. 2022 Nov 17:S0302-2838(22)02780-4. doi: 10.1016/j.eururo.2022.
    PubMed     Abstract available


  2. ALBERTSEN PC
    Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues.
    Eur Urol. 2022 Nov 10. pii: S0302-2838(22)02772.
    PubMed    


  3. HU M, Ye L
    Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551-58.
    Eur Urol. 2022 Nov 7. pii: S0302-2838(22)02779.
    PubMed    


  4. SHENDEROV E, Antonarakis ES
    B7-H3 and Prostate Cancer: New Therapeutic Dance Partners.
    Eur Urol. 2022 Nov 5. pii: S0302-2838(22)02773.
    PubMed    


  5. YAO X, Duan C, Li B, Wu X, et al
    Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Stu
    Eur Urol. 2022 Nov 2. pii: S0302-2838(22)02720.
    PubMed    


  6. CARLSSON SV, Arnsrud Godtman R, Pihl CG, Vickers A, et al
    Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial.
    Eur Urol. 2022 Nov 2. pii: S0302-2838(22)02715.
    PubMed     Abstract available


  7. XU P, Chen C, Chen B, Bi E, et al
    Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre.
    Eur Urol. 2022;82:543-550.
    PubMed     Abstract available


  8. MARTINI A, Mottet N, Montorsi F, Necchi A, et al
    A Plea for Economically Sustainable Evidence-based Guidelines.
    Eur Urol. 2022;82:449-451.
    PubMed     Abstract available


    October 2022
  9. FERGUSON EL, Kaouk JH
    Reply to Minxiong Hu and Liefu Ye's Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique.
    Eur Urol. 2022 Oct 25. pii: S0302-2838(22)02722.
    PubMed    


  10. AYATI N, Herrmann K, Fanti S, Murphy DG, et al
    More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Oct 21. pii: S0302-2838(22)02714.
    PubMed     Abstract available


  11. FERGUSON EL, Kaouk JH
    Reply to Shangqing Ren, Xu Hu, Kai Wang, Qian Lv, and Wang Dong's Letter to the Editor re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series
    Eur Urol. 2022 Oct 21. pii: S0302-2838(22)02717.
    PubMed    


  12. VANDEKERKHOVE G
    BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2022 Oct 20. pii: S0302-2838(22)02708.
    PubMed    


  13. REN S, Hu X, Wang K, Lv Q, et al
    Re: Jihad H. Kaouk, Ethan L. Ferguson, Alp Tuna Beksac, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022;82:551-58.
    Eur Urol. 2022 Oct 19. pii: S0302-2838(22)02716.
    PubMed    


  14. DE BARROS HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, et al
    Reply to Xiangyang Yao, Chen Duan, Bo Li, Xiaoliang Wu and Hua Xu's Letter to the Editor Re: Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Rec
    Eur Urol. 2022 Oct 19. pii: S0302-2838(22)02718.
    PubMed    


  15. LOEHR A, Hussain A, Patnaik A, Bryce AH, et al
    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
    Eur Urol. 2022 Oct 12. pii: S0302-2838(22)02639.
    PubMed     Abstract available


  16. WANG B, Li C, Zheng X, Yao K, et al
    Re: Giorgio Gandaglia, Elio Mazzone, Armando Stabile, et al. Prostate-specific Membrane Antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymp
    Eur Urol. 2022 Oct 6. pii: S0302-2838(22)02696.
    PubMed    


  17. JACOBS MF, Greenberg SE
    Prostate Cancer Genomic Testing: When Sequencing Is Not Sufficient and Germline Testing Is Necessary.
    Eur Urol. 2022 Oct 5. pii: S0302-2838(22)02690.
    PubMed    


  18. MAXWELL KN, Pritchard CC
    Reply to Hela Sassi, Olivier Caron, and Etienne Rouleau's Letter to the Editor re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50.
    Eur Urol. 2022 Oct 3. pii: S0302-2838(22)02698.
    PubMed    


    September 2022
  19. HALL WA, Shoag J, Spratt DE
    Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study.
    Eur Urol. 2022 Sep 29. pii: S0302-2838(22)02618.
    PubMed    


  20. DEVOS G, Tosco L, Baldewijns M, Gevaert T, et al
    ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Eur Urol. 2022 Sep 24. pii: S0302-2838(22)02638.
    PubMed     Abstract available


  21. SCHILHAM MGM, Rijpkema M, Scheenen T, Hermsen R, et al
    How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come.
    Eur Urol. 2022 Sep 24. pii: S0302-2838(22)02634.
    PubMed     Abstract available


  22. SASSI H, Caron O, Rouleau E
    Re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50: Off-core Li-Fraumeni Syndrome Spectrum Cancers: Increasing Interest for Prostate Cancer?
    Eur Urol. 2022 Sep 21. pii: S0302-2838(22)02632.
    PubMed    


  23. BARNETT ES, Schultz N, Stopsack KH, Lam ET, et al
    Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2022 Sep 16. pii: S0302-2838(22)02561.
    PubMed     Abstract available


  24. ZAPATERO A, Calvo FA, Gonzalez San-Segundo C, Alvarez A, et al
    Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2
    Eur Urol. 2022 Sep 14. pii: S0302-2838(22)02624.
    PubMed    


  25. TRUONG H, Breen K, Nandakumar S, Sjoberg DD, et al
    Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
    Eur Urol. 2022 Sep 14. pii: S0302-2838(22)02619.
    PubMed     Abstract available


  26. GUO C, Figueiredo I, Gurel B, Neeb A, et al
    B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02633.
    PubMed     Abstract available


  27. DZIMITROWICZ HE, Armstrong AJ
    Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment.
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02621.
    PubMed    


  28. LEE DJ, Hausler R, Maxwell KN
    Reply to Joanne L. Dickinson, Georgea R. Foley, and Liesel M. FitzGerald's Letter to the Editor re: Daniel J. Lee, Ryan Hausler, Anh N. Le, et al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. Eur Urol 2022;81:
    Eur Urol. 2022 Sep 13. pii: S0302-2838(22)02616.
    PubMed    


  29. OLIVIER T, Powell K, Prasad V
    Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.
    Eur Urol. 2022 Sep 9. pii: S0302-2838(22)02613.
    PubMed     Abstract available


  30. BOGEMANN M, Shore ND, Smith MR, Tammela TLJ, et al
    Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
    Eur Urol. 2022 Sep 8. pii: S0302-2838(22)02532.
    PubMed     Abstract available


  31. LI H, Zhang Y, Xu H
    Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp's Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metast
    Eur Urol. 2022 Sep 7. pii: S0302-2838(22)02565.
    PubMed    


  32. DICKINSON JL, Foley GR, FitzGerald LM
    Re: Daniel J. Lee, Ryan Hausler, Anh N. Le, et al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. Eur Urol 2022;81:559-67.
    Eur Urol. 2022 Sep 5. pii: S0302-2838(22)02617.
    PubMed    


  33. MONTORSI F, Bravi CA, Gandaglia G, Mottrie A, et al
    Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surge
    Eur Urol. 2022 Sep 2. pii: S0302-2838(22)02612.
    PubMed    


  34. BRISBANE WG, Priester AM, Ballon J, Kwan L, et al
    Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
    Eur Urol. 2022;82:303-310.
    PubMed     Abstract available


    August 2022
  35. YU EY, Piulats JM, Gravis G, Fong PCC, et al
    Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
    Eur Urol. 2022 Aug 30. pii: S0302-2838(22)02554.
    PubMed     Abstract available


  36. SOWALSKY AG, Plymate SR, Haffner MC, de Bono JS, et al
    Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86 AR-V7 is Rare in Horm
    Eur Urol. 2022 Aug 26. pii: S0302-2838(22)02563.
    PubMed    


  37. YANAGISAWA T, Rajwa P, Thibault C, Gandaglia G, et al
    Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2022 Aug 19. pii: S0302-2838(22)02551.
    PubMed     Abstract available


  38. CHANG D, Blanchard P, Siva S
    The Deep Blue of Prostate Cancer Metastasis Evolution: The LEVIATHAN Pooled Analysis.
    Eur Urol. 2022 Aug 19. pii: S0302-2838(22)02555.
    PubMed    


  39. MONTORSI F, Gandaglia G, Robesti D, Deho F, et al
    Re: Kathia De Man, Nick Van Laeken, Vanessa Schelfhout, et al. (18)F-PSMA-11 Versus (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-
    Eur Urol. 2022 Aug 18. pii: S0302-2838(22)02557.
    PubMed    


  40. GRIVAS N, Lardas M, Espinos EL, Lam TB, et al
    Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review.
    Eur Urol. 2022 Aug 16. pii: S0302-2838(22)02540.
    PubMed     Abstract available


  41. KAOUK JH, Ferguson EL, Beksac AT, Zeinab MA, et al
    Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique.
    Eur Urol. 2022 Aug 12. pii: S0302-2838(22)02531.
    PubMed     Abstract available


  42. PETERS M, Eldred-Evans D, Kurver P, Falagario UG, et al
    Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert >/=3 Lesion: Development and Multinational External Validation of
    Eur Urol. 2022 Aug 10. pii: S0302-2838(22)02537.
    PubMed     Abstract available


  43. DASGUPTA P
    Re: Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer: The PANDA Challenge.
    Eur Urol. 2022 Aug 9. pii: S0302-2838(22)02543.
    PubMed    


  44. KESCH C, Hadaschik BA
    Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.
    Eur Urol. 2022 Aug 9. pii: S0302-2838(22)02546.
    PubMed    


  45. DORFF TB, Morgans AK
    A Path to Precision Medicine in Prostate Cancer: Learning from "Negative" Trials of Targeted Therapies.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02527.
    PubMed    


  46. CARVALHO FLF, Mossanen M, Van Allen EM, Mouw KW, et al
    Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02534.
    PubMed    


  47. SONG Y, Du Y, Xu T
    Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 5. pii: S0302-2838(22)02530.
    PubMed    


  48. MA TM, Chu FI, Sandler H, Feng FY, et al
    Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
    Eur Urol. 2022 Aug 4. pii: S0302-2838(22)02523.
    PubMed     Abstract available


  49. WASHINGTON SL
    We Must Change Our Approach to Racial Disparities in Prostate Cancer.
    Eur Urol. 2022 Aug 4. pii: S0302-2838(22)02529.
    PubMed    


  50. MEISSNER VH, Rauscher I, Schwamborn K, Neumann J, et al
    Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography.
    Eur Urol. 2022;82:156-160.
    PubMed     Abstract available


    July 2022
  51. BOSAS P, Zaleskis G, Characiejus D
    Re: Sylvia H.J. Jochems, Josef Fritz, Christel Haggstrom, Bengt Jarvholm, Par Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02478.
    PubMed    


  52. VILASECA A, Ribal MJ
    Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02526.
    PubMed    


  53. JOCHEMS SHJ, Stattin P, Stocks T
    Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Haggstrom, Bengt Jarvholm, Par Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Deat
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02481.
    PubMed    


  54. MURTHY V, Chilukuri S, Maitre P
    Re: Pawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2022;82:82-96.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02480.
    PubMed    


  55. LEVERIDGE M, Siemens DR
    Re: Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
    Eur Urol. 2022 Jul 27. pii: S0302-2838(22)02528.
    PubMed    


  56. BOKHORST LP, Heesterman BL
    Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial.
    Eur Urol. 2022 Jul 25. pii: S0302-2838(22)02482.
    PubMed    


  57. GANDAGLIA G, Mazzone E, Stabile A, Pellegrino A, et al
    Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a
    Eur Urol. 2022 Jul 22. pii: S0302-2838(22)02417.
    PubMed     Abstract available


  58. SAMARATUNGA H, Delahunt B, Egevad L
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;82:e15-e16.
    PubMed    


  59. PADHANI AR, Schoots IG, Giannarini G
    Re: Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
    Eur Urol. 2022;82:143-144.
    PubMed    


  60. LENFANT L, Barret E, Roupret M, Rozet F, et al
    Transperineal Prostate Biopsy Is the New Black: What Are the Next Targets?
    Eur Urol. 2022;82:3-5.
    PubMed     Abstract available


  61. VAN LEEUWEN PJ, Emmett L
    (18)F-PSMA-11 as an Attractive (68)Ga-PSMA-11 Alternative for Prostate Cancer Imaging.
    Eur Urol. 2022 Jul 1. pii: S0302-2838(22)02416.
    PubMed    


    June 2022
  62. MARRA G, Agnello M, Giordano A, Soria F, et al
    Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series.
    Eur Urol. 2022 Jun 21. pii: S0302-2838(22)02400.
    PubMed     Abstract available


  63. SAAD F, de Bono J, Barthelemy P, Dorff T, et al
    Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
    Eur Urol. 2022 Jun 21. pii: S0302-2838(22)02407.
    PubMed     Abstract available


  64. KNIPPER S, Mehdi Irai M, Simon R, Koehler D, et al
    Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
    Eur Urol. 2022 Jun 16. pii: S0302-2838(22)02408.
    PubMed     Abstract available


  65. VICKERS AJ
    Corrigendum to "Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer" [Eur Urol 2021;80:567-72].
    Eur Urol. 2022 Jun 14. pii: S0302-2838(22)02398.
    PubMed    


  66. DE MAN K, Van Laeken N, Schelfhout V, Fendler WP, et al
    (18)F-PSMA-11 Versus (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.
    Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02383.
    PubMed     Abstract available


  67. REDDY D, Ahmed HU
    Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focus
    Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02412.
    PubMed    


  68. KISHAN AU, Spratt DE
    Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02410.
    PubMed    


  69. BEYER K, MacLennan S, Van Hemelrijck M
    Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resi
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02388.
    PubMed    


  70. CRABB SJ, Griffiths G, Dunkley D, Downs N, et al
    Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02393.
    PubMed     Abstract available


  71. LAO Y, Wang Y, Dong Z
    Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
    Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02411.
    PubMed    


  72. ROCCO B, Sighinolfi MC, Coelho RF, Covas Moschovas M, et al
    Re: Trends in Incidence of Metastatic Prostate Cancer in the US.
    Eur Urol. 2022 Jun 2. pii: S0302-2838(22)02271.
    PubMed    


  73. MONTORSI F, Stabile A, Mazzone E, Gandaglia G, et al
    Re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Eur Urol 2022;81:407-13
    Eur Urol. 2022 Jun 2. pii: S0302-2838(22)02394.
    PubMed    


    May 2022
  74. BURNS D, Anokian E, Saunders EJ, Bristow RG, et al
    Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
    Eur Urol. 2022 May 31. pii: S0302-2838(22)02341.
    PubMed     Abstract available


  75. PLYM A, Zhang Y, Stopsack KH, Delcoigne B, et al
    A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer.
    Eur Urol. 2022 May 27. pii: S0302-2838(22)02342.
    PubMed     Abstract available


  76. LEI R, Li Y, Chen Y
    Re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 202
    Eur Urol. 2022 May 26. pii: S0302-2838(22)02387.
    PubMed    


  77. WEI Y, Ye D, Zhu Y
    Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)02339.
    PubMed    


  78. SONG Y, Du Y, Xu T
    Re: Jiatong Zhou, Jie Ding, Jun Qi. Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis. Eur Urol.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)02334.
    PubMed    


  79. BERLIN A, Brierley J, Cornford P, Chung P, et al
    TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification.
    Eur Urol. 2022 May 10. pii: S0302-2838(22)02267.
    PubMed    


  80. RAKAUSKAS A, Valerio M, Roth B
    Re: Multiparametric Ultrasound Versus Multiparametric MRI To Diagnose Prostate Cancer (CADMUS): A Prospective, Multicentre, Paired-cohort, Confirmatory Study.
    Eur Urol. 2022 May 4. pii: S0302-2838(22)01815.
    PubMed    


  81. JOCHEMS SHJ, Fritz J, Haggstrom C, Jarvholm B, et al
    Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study.
    Eur Urol. 2022 May 3. pii: S0302-2838(22)01804.
    PubMed     Abstract available


  82. MARRA G, Stabile A, Gontero P, Montorsi F, et al
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;81:e115-e116.
    PubMed    


  83. LEI Y, Han S, Xing N
    Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In pr
    Eur Urol. 2022;81:e121.
    PubMed    


    April 2022
  84. KISHAN AU, Wang X, Sun Y, Romero T, et al
    High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
    Eur Urol. 2022 Apr 22. pii: S0302-2838(22)01808.
    PubMed     Abstract available


  85. RAJWA P, Pradere B, Gandaglia G, van den Bergh RCN, et al
    Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2022 Apr 21. pii: S0302-2838(22)01802.
    PubMed     Abstract available


  86. GILLESSEN S, Armstrong A, Attard G, Beer TM, et al
    Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
    Eur Urol. 2022 Apr 18. pii: S0302-2838(22)01807.
    PubMed     Abstract available


  87. TURCO F, Armstrong A, Attard G, Beer TM, et al
    Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022].
    Eur Urol. 2022 Apr 16. pii: S0302-2838(22)01809.
    PubMed    


  88. YU EY, Kolinsky MP, Berry WR, Retz M, et al
    Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Eur Urol. 2022 Apr 6. pii: S0302-2838(22)01665.
    PubMed     Abstract available


  89. THOMAN ME, Salari K
    Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2022 Apr 5. pii: S0302-2838(22)01787.
    PubMed    


  90. DI LORENZO G, Buonerba C
    Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2119115.
    Eur Urol. 2022 Apr 4. pii: S0302-2838(22)01675.
    PubMed    


  91. GAUTHE M, Sargos P, Benziane Ouaritini N, Barret E, et al
    Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [(68)Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management.
    Eur Urol. 2022;81:e87-e89.
    PubMed    


  92. LEI Y, Zhang Y, Xing N
    Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.
    Eur Urol. 2022;81:e96-e97.
    PubMed    


  93. SOOD A, Jeong W, Palma-Zamora I, Abdollah F, et al
    Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study).
    Eur Urol. 2022;81:396-406.
    PubMed     Abstract available


    March 2022
  94. SHAH TT, Kanthabalan A, Otieno M, Pavlou M, et al
    Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.
    Eur Urol. 2022 Mar 31. pii: S0302-2838(22)01664.
    PubMed     Abstract available


  95. HAO S, Heintz E, Ostensson E, Discacciati A, et al
    Corrigendum to "Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study" [Eur Urol 2022].
    Eur Urol. 2022 Mar 30. pii: S0302-2838(22)01796.
    PubMed    


  96. NYAME YA, Cooperberg MR, Cumberbatch MG, Eggener SE, et al
    Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care.
    Eur Urol. 2022 Mar 30. pii: S0302-2838(22)01677.
    PubMed     Abstract available


  97. BJARTELL A
    Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Eur Urol. 2022 Mar 29. pii: S0302-2838(22)01791.
    PubMed    


  98. PUSHKAR D, Govorov A
    Re: Survival After Radical Prostatectomy Versus Radiation Therapy in High-risk and Very High-risk Prostate Cancer.
    Eur Urol. 2022 Mar 29. pii: S0302-2838(22)01794.
    PubMed    


  99. WEI Y, Zhu Y, Ye D
    Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. In press. https://doi.org/10.101
    Eur Urol. 2022 Mar 28. pii: S0302-2838(22)01801.
    PubMed    


  100. TURCO F, Smith M, Omlin A, Gillessen S, et al
    Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Conse
    Eur Urol. 2022 Mar 28. pii: S0302-2838(22)01800.
    PubMed    


  101. MARTINI A, Ploussard G
    Re: Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01792.
    PubMed    


  102. CHEN K, McVey A, Kasivisvanathan V, Jenjitranant P, et al
    Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Mar 25. pii: S0302-2838(22)01789.
    PubMed    


  103. WAGENSVELD IM, Osses DF, Groenendijk PM, Zijta FM, et al
    A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naive Men.
    Eur Urol. 2022 Mar 24. pii: S0302-2838(22)01673.
    PubMed     Abstract available


  104. KERKMEIJER LGW, Pos FJ, van der Heide UA, Israel B, et al
    Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial f
    Eur Urol. 2022 Mar 23. pii: S0302-2838(22)01674.
    PubMed    


  105. DE BARROS HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, et al
    Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
    Eur Urol. 2022 Mar 23. pii: S0302-2838(22)01672.
    PubMed     Abstract available


  106. HEIDEGGER I, Pircher A
    Re: Qing Cheng, William Butler, Yinglu Zhou, et al. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.039.
    Eur Urol. 2022 Mar 11. pii: S0302-2838(22)01667.
    PubMed    


  107. NG A, Khetrapal P, Kasivisvanathan V
    Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?
    Eur Urol. 2022 Mar 8. pii: S0302-2838(22)01663.
    PubMed     Abstract available


  108. VAN DER POEL H
    Re: Radical Prostatectomy for Localized Prostate Cancer: 20-Year Oncological Outcomes from a German High-volume Center.
    Eur Urol. 2022 Mar 2. pii: S0302-2838(22)01658.
    PubMed    


    February 2022
  109. SAHU KK
    Re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press
    Eur Urol. 2022 Feb 26. pii: S0302-2838(22)01662.
    PubMed    


  110. ZHOU J, Ding J, Qi J
    Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis.
    Eur Urol. 2022 Feb 24. pii: S0302-2838(22)01645.
    PubMed     Abstract available


  111. ALI A, Baena E
    The Needle in the Haystack: The Presence of Castrate-resistant Prostate Cancer Cells in Hormone-naive Prostate Cancer.
    Eur Urol. 2022 Feb 24. pii: S0302-2838(22)01609.
    PubMed    


  112. VICKERS AJ, Elfiky A, Freeman V, Roach M 3rd, et al
    Race, Biology, Disparities, and Prostate Cancer.
    Eur Urol. 2022 Feb 22. pii: S0302-2838(22)01646.
    PubMed    


  113. GRUNWALD V, Ohlmann CH, Hadaschik B
    Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol.
    Eur Urol. 2022 Feb 19. pii: S0302-2838(22)01648.
    PubMed    


  114. BEYER K, Moris L, Lardas M, Omar MI, et al
    Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.
    Eur Urol. 2022 Feb 17. pii: S0302-2838(22)00085.
    PubMed     Abstract available


  115. TURCO F, Armstrong A, Attard G, Beer TM, et al
    What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
    Eur Urol. 2022 Feb 17. pii: S0302-2838(22)01650.
    PubMed     Abstract available


  116. MONTORSI F, Stabile A, Gandaglia G, Briganti A, et al
    Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol 2022;81:5-33.
    Eur Urol. 2022 Feb 9. pii: S0302-2838(22)00078.
    PubMed    


  117. HEIJNSDIJK EAM, de Koning HJ
    Improved Harm/Benefit Ratio and Cost-effectiveness of Prostate Cancer Screening Using New Technologies.
    Eur Urol. 2022 Feb 4. pii: S0302-2838(22)00075.
    PubMed    


  118. REDDY D, Peters M, Shah TT, van Son M, et al
    Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
    Eur Urol. 2022 Feb 2. pii: S0302-2838(22)00006.
    PubMed     Abstract available


  119. GODTMAN RA, Kollberg KS, Pihl CG, Mansson M, et al
    The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Goteborg-1 Prostate Cancer Screening Trial.
    Eur Urol. 2022 Feb 1. pii: S0302-2838(22)00019.
    PubMed     Abstract available


  120. SAAD F, Small EJ, Feng FY, Graff JN, et al
    Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Eur Urol. 2022;81:184-192.
    PubMed     Abstract available


  121. MAZZONE E, Gandaglia G, Ploussard G, Marra G, et al
    Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
    Eur Urol. 2022;81:193-203.
    PubMed     Abstract available


    January 2022
  122. ZUMSTEG ZS
    Simultaneous Integrated Micro-boost: Reigniting the FLAME for Dose Escalation in Prostate Cancer?
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00064.
    PubMed    


  123. BRAUN A, Abbosh PH
    Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy: A Rare Entity with Unique Genomic Features.
    Eur Urol. 2022 Jan 30. pii: S0302-2838(22)00067.
    PubMed    


  124. MARKT SC, Penney KL, Schumacher FR
    Finding a Place for Family History To Inform High-grade Prostate Cancer Risk.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00066.
    PubMed    


  125. RASLAN M, Mercader C, Lamb AD
    Re: Prostate Cancer Screening Using a Combination of Risk-prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-based, Randomised, Open-label, Non-inferiority Trial.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00021.
    PubMed    


  126. WALZ J
    Re: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial.
    Eur Urol. 2022 Jan 29. pii: S0302-2838(22)00016.
    PubMed    


  127. WITHINGTON J, Moore CM
    Active Surveillance for Prostate Cancer: Will Magnetic Resonance Imaging Help Us Address the Current Controversies in Traditional Surveillance Approaches?
    Eur Urol. 2022 Jan 28. pii: S0302-2838(22)00007.
    PubMed    


  128. MASON MD, van der Kwast TH, Mottet N, Oprea-Lager DE, et al
    Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?
    Eur Urol. 2022 Jan 27. pii: S0302-2838(22)00003.
    PubMed     Abstract available


  129. HAO S, Heintz E, Ostensson E, Discacciati A, et al
    Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
    Eur Urol. 2022 Jan 27. pii: S0302-2838(21)02269.
    PubMed     Abstract available


  130. DI LALLA V, Kucharczyk MJ, Wyatt AW, Feng FY, et al
    Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2022 Jan 19. pii: S0302-2838(21)02287.
    PubMed     Abstract available


  131. CHENG Q, Butler W, Zhou Y, Zhang H, et al
    Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Eur Urol. 2022 Jan 17. pii: S0302-2838(22)00001.
    PubMed     Abstract available


  132. DARST BF, Hughley R, Pfennig A, Hazra U, et al
    A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02271.
    PubMed     Abstract available


  133. OZEN H, Turkeri L
    Re: Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02277.
    PubMed    


  134. DEVLIES W, Devos G, Decloedt H, Vansevenant B, et al
    Re: Molecular Features of Exceptional Response to Neoadjuvant Anti-androgen Therapy in High-risk Localized Prostate Cancer.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02275.
    PubMed    


  135. SKOTHEIM RI, Axcrona U, Axcrona K
    Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.
    Eur Urol. 2022 Jan 11. pii: S0302-2838(21)02280.
    PubMed    


  136. GREENBERG SE, Jacobs MF
    Continuing the Evolution of Germline Genetics in Prostate Cancer: Tailoring Testing To Enhance Patient Care.
    Eur Urol. 2022 Jan 10. pii: S0302-2838(21)02268.
    PubMed    


  137. FLESHNER K, Carlsson SV
    Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
    Eur Urol. 2022 Jan 10. pii: S0302-2838(21)02276.
    PubMed    


  138. SINGH J
    Re: Marc Sbizzera, Nicolas Morel-Journal, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. Eur Urol. In press.
    Eur Urol. 2022 Jan 7. pii: S0302-2838(21)02210.
    PubMed    


  139. MOROTE J, Diaz F, Celma A, Planas J, et al
    Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.
    Eur Urol. 2022;81:124-125.
    PubMed    


  140. HOFMANN M, Huang E, Huynh LM, Kaler K, et al
    Retrospective Concomitant Nonrandomized Comparison of "Touch" Cautery Versus Athermal Dissection of the Prostatic Vascular Pedicles and Neurovascular Bundles During Robot-assisted Radical Prostatectomy.
    Eur Urol. 2022;81:104-109.
    PubMed     Abstract available


    December 2021
  141. CLEMENTS MB, Vertosick EA, Guerrios-Rivera L, De Hoedt AM, et al
    Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort.
    Eur Urol. 2021 Dec 31. pii: S0302-2838(21)02222.
    PubMed     Abstract available


  142. WILLEMSE PM, Davis NF, Grivas N, Zattoni F, et al
    Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
    Eur Urol. 2021 Dec 31. pii: S0302-2838(21)02215.
    PubMed     Abstract available


  143. GROEN VH, Haustermans K, Pos FJ, Draulans C, et al
    Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02223.
    PubMed     Abstract available


  144. MOSSANEN M, Carvalho FLF, Muralidhar V, Preston MA, et al
    Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Eur Urol. 2021 Dec 22. pii: S0302-2838(21)02212.
    PubMed     Abstract available


  145. SBIZZERA M, Morel-Journel N, Carnicelli D, Ruffion A, et al
    Reply to Jas Singh's Letter to the Editor re: Marc Sbizzera, Nicolas Morel-Journel, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Musc
    Eur Urol. 2021 Dec 18. pii: S0302-2838(21)02209.
    PubMed    


  146. GRUMMET J, Eggener S
    Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02201.
    PubMed    


  147. CASTRO E
    TP53: Another Piece of the Prostate Cancer Genetics Puzzle.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02199.
    PubMed    


  148. FASULO V, Zuradelli M, Lazzeri M
    Re: A Prospective Prostate Cancer Screening Programme for Men with Pathogenic Variants in Mismatch Repair Genes (IMPACT): Initial Results from an International Prospective Study.
    Eur Urol. 2021 Dec 9. pii: S0302-2838(21)02206.
    PubMed    


  149. SWAMI U, Sayegh N, Agarwal N
    Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer.
    Eur Urol. 2021 Dec 8. pii: S0302-2838(21)02200.
    PubMed    


  150. MAXWELL KN, Cheng HH, Powers J, Gulati R, et al
    Inherited TP53 Variants and Risk of Prostate Cancer.
    Eur Urol. 2021 Dec 1. pii: S0302-2838(21)02139.
    PubMed     Abstract available


  151. ROCCO B, Sarchi L, Assumma S, Cimadamore A, et al
    Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique.
    Eur Urol. 2021;80:724-729.
    PubMed     Abstract available


    November 2021
  152. NGUYEN AT, Kamrava M
    Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, Massimo Valerio, Jurgen J. Futterer, Maroeska M. Rovers. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. In
    Eur Urol. 2021 Nov 27. pii: S0302-2838(21)02159.
    PubMed    


  153. LANTZ A, Bock D, Akre O, Angenete E, et al
    Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Ca
    Eur Urol. 2021 Nov 24. pii: S0302-2838(21)02150.
    PubMed    


  154. WILT TJ, Vo TN, Langsetmo L, Dahm P, et al
    Corrigendum re: "Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)" [Eur Urol 2020;77:713-24].
    Eur Urol. 2021 Nov 23. pii: S0302-2838(21)02157.
    PubMed    


  155. SO WZ, Wang Z, Tiong HY
    Re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650-60.
    Eur Urol. 2021 Nov 22. pii: S0302-2838(21)02140.
    PubMed    


  156. IMMERZEEL J, Israel B, Bomers J, Schoots IG, et al
    Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance-Ultrasound Fusion Guided Biopsy Using Local Anesthesia.
    Eur Urol. 2021 Nov 16. pii: S0302-2838(21)02135.
    PubMed     Abstract available


  157. BACIARELLO G, Delva R, Gravis G, Tazi Y, et al
    Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
    Eur Urol. 2021 Nov 14. pii: S0302-2838(21)02117.
    PubMed     Abstract available


  158. PANSADORO V, Brassetti A
    Re: Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histolo
    Eur Urol. 2021 Nov 13. pii: S0302-2838(21)02125.
    PubMed    


  159. SCHMID HP, Hechelhammer L, Mullhaupt G
    Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer Under Active Surveillance: Cancer Prostate Embolisation, a Pilot Study.
    Eur Urol. 2021 Nov 9. pii: S0302-2838(21)02128.
    PubMed    


  160. DE KOUCHKOVSKY I, Chen HY, Ohliger MA, Wang ZJ, et al
    Hyperpolarized 1-[(13)C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer.
    Eur Urol. 2021 Nov 7. pii: S0302-2838(21)02116.
    PubMed    


  161. BELTRAN H, Morgans AK
    Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology.
    Eur Urol. 2021 Nov 3. pii: S0302-2838(21)02131.
    PubMed    


  162. ABREU AL, Kaneko M, Cacciamani GE, Lebastchi AH, et al
    Focal Therapy for Prostate Cancer: Getting Ready for Prime Time.
    Eur Urol. 2021 Nov 2. pii: S0302-2838(21)02073.
    PubMed    


  163. KAZYBAY B, Xie Y
    Re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.024.
    Eur Urol. 2021;80:e115-e116.
    PubMed    


  164. COELINGH BENNINK HJT, Foidart JM, Debruyne FMJ
    Reply to Bexultan Kazybay and Yingqiu Xie's Letter to the Editor re: Herjan J.T. Coelingh Bennink, Jean-Michel Foidart, Frans M.J. Debruyne. Treatment of Serious COVID-19 with Testosterone Suppression and High-dose Estrogen Therapy. Eur Urol. In press
    Eur Urol. 2021;80:e117-e118.
    PubMed    


    October 2021
  165. VAN POPPEL H, Roobol MJ
    Reply to Takeshi Takahashi's Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association
    Eur Urol. 2021 Oct 28. pii: S0302-2838(21)02072.
    PubMed    


  166. TAKAHASHI T
    Re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
    Eur Urol. 2021 Oct 26. pii: S0302-2838(21)02071.
    PubMed    


  167. GRAF RP, Fisher V, Mateo J, Gjoerup OV, et al
    Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Oct 26. pii: S0302-2838(21)02060.
    PubMed     Abstract available


  168. LEE DJ, Hausler R, Le AN, Kelly G, et al
    Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Eur Urol. 2021 Oct 25. pii: S0302-2838(21)02059.
    PubMed     Abstract available


  169. SBIZZERA M, Morel-Journel N, Ruffion A, Crouzet S, et al
    Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition.
    Eur Urol. 2021 Oct 19. pii: S0302-2838(21)02041.
    PubMed     Abstract available


  170. OST P, Siva S, Zilli T
    Everything But the Kitchen Sink: Comprehensive Nodal Irradiation with Androgen Deprivation in OLIGOPELVIS.
    Eur Urol. 2021;80:415-416.
    PubMed    


  171. BIANCHI L, Chessa F, Angiolini A, Cercenelli L, et al
    The Use of Augmented Reality to Guide the Intraoperative Frozen Section During Robot-assisted Radical Prostatectomy.
    Eur Urol. 2021;80:480-488.
    PubMed     Abstract available


  172. WURNSCHIMMEL C, Pose RM, Wenzel M, Tian Z, et al
    Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort.
    Eur Urol. 2021;80:400-404.
    PubMed     Abstract available


    September 2021
  173. VICKERS AJ
    Reply to Francesco Montorsi, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. In press. https://doi.o
    Eur Urol. 2021 Sep 29. pii: S0302-2838(21)02050.
    PubMed    


  174. MONTORSI F, Gandaglia G, Briganti A
    Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.06.026.
    Eur Urol. 2021 Sep 28. pii: S0302-2838(21)02051.
    PubMed    


  175. REN S, Yang B, Wang D
    Re: Vicenc Ruiz de Porras, Xieng C. Wang, Luis Palomero, et al. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol 2021;79:722-33.
    Eur Urol. 2021 Sep 25. pii: S0302-2838(21)02018.
    PubMed    


  176. TRELLES CR, Martinez-Pineiro L
    Re: The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
    Eur Urol. 2021 Sep 24. pii: S0302-2838(21)02000.
    PubMed    


  177. HAGENS MJ, van Leeuwen PJ
    A Future Prebiopsy Imaging-guided Pathway to Safely Omit Systematic Biopsies and Prevent Diagnosis of Indolent Prostate Cancer.
    Eur Urol. 2021 Sep 21. pii: S0302-2838(21)02002.
    PubMed    


  178. LANTZ A, Bock D, Akre O, Angenete E, et al
    Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up.
    Eur Urol. 2021 Sep 15. pii: S0302-2838(21)01928.
    PubMed     Abstract available


  179. GHALI F, Kane CJ
    Re: Association of Black Race with Prostate Cancer-specific and Other-cause Mortality.
    Eur Urol. 2021 Sep 14. pii: S0302-2838(21)01999.
    PubMed    


  180. ALAN MCNEILL S, Gallagher KM, Clyde D
    Re: A Biochemical Definition of Cure After Brachytherapy for Prostate Cancer.
    Eur Urol. 2021 Sep 13. pii: S0302-2838(21)01995.
    PubMed    


  181. SHOAG JE, Hill A, Jung JH, Spratt D, et al
    Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial.
    Eur Urol. 2021 Sep 10. pii: S0302-2838(21)01988.
    PubMed    


  182. KWAN EM, Spain L, Anton A, Gan CL, et al
    Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
    Eur Urol. 2021 Sep 4. pii: S0302-2838(21)01979.
    PubMed     Abstract available


  183. THURTLE D, Jenkins V, Freeman A, Pearson M, et al
    Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial.
    Eur Urol. 2021 Sep 4. pii: S0302-2838(21)01933.
    PubMed     Abstract available


  184. HOPSTAKEN JS, Bomers JGR, Sedelaar MJP, Valerio M, et al
    An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?
    Eur Urol. 2021 Sep 3. pii: S0302-2838(21)01949.
    PubMed     Abstract available


  185. LIU W, Zukotynski K, Bauman G
    Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374-
    Eur Urol. 2021;80:e77-e78.
    PubMed    


    August 2021
  186. EMMETT L, Buteau J, Papa N, Moon D, et al
    The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Eur Urol. 2021 Aug 28. pii: S0302-2838(21)01946.
    PubMed     Abstract available


  187. VAN POPPEL H, Roobol MJ, Chapple CR, Catto JWF, et al
    Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
    Eur Urol. 2021 Aug 15. pii: S0302-2838(21)01927.
    PubMed     Abstract available


  188. LORENTE D, Llacer C, Lozano R, de Velasco G, et al
    Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
    Eur Urol. 2021 Aug 6. pii: S0302-2838(21)01917.
    PubMed     Abstract available


  189. VENTIMIGLIA E, Pozzi E, Alfano M, Montorsi F, et al
    Re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Microbiomes in Male Infertility. Eur Urol 2021;79:826-36.
    Eur Urol. 2021;80:e53-e54.
    PubMed    


  190. GUPTA S, Pitel BA, Knight SM, Halling KC, et al
    Re: Stanley Weng, Renzo G. DiNatale, Andrew Silagy, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. Eur Urol 2021;79:468-77.
    Eur Urol. 2021;80:e62-e63.
    PubMed    


  191. LUNDY SD, Vij SC, Eng C
    Reply to Eugenio Ventimiglia, Edoardo Pozzi, Massimo Alfano, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Micro
    Eur Urol. 2021;80:e55-e56.
    PubMed    


  192. MEIJER D, van Leeuwen PJ, Roberts MJ, Siriwardana AR, et al
    External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study.
    Eur Urol. 2021;80:234-242.
    PubMed     Abstract available


  193. ROBINSON AG, Izard JP, Vera-Badillo FE
    Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
    Eur Urol. 2021;80:123-126.
    PubMed     Abstract available


  194. WAGASKAR VG, Mittal A, Sobotka S, Ratnani P, et al
    Hood Technique for Robotic Radical Prostatectomy-Preserving Periurethral Anatomical Structures in the Space of Retzius and Sparing the Pouch of Douglas, Enabling Early Return of Continence Without Compromising Surgical Margin Rates.
    Eur Urol. 2021;80:213-221.
    PubMed     Abstract available


    July 2021
  195. HADASCHIK B, Herrmann K
    Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Jul 23. pii: S0302-2838(21)01885.
    PubMed    


  196. VICKERS AJ
    Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer.
    Eur Urol. 2021 Jul 19. pii: S0302-2838(21)01867.
    PubMed     Abstract available


  197. STERNBERG CN, Castellano D, de Bono J, Fizazi K, et al
    Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Eur Urol. 2021 Jul 14. pii: S0302-2838(21)01862.
    PubMed     Abstract available


  198. ATTARD G, Brown LC, Clarke NW, Parmar MKB, et al
    Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial.
    Eur Urol. 2021 Jul 14. pii: S0302-2838(21)01864.
    PubMed    


  199. SUPIOT S, Vaugier L, Pasquier D, Buthaud X, et al
    OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
    Eur Urol. 2021 Jul 8. pii: S0302-2838(21)01816.
    PubMed     Abstract available


  200. MARSDEN T, Ahmed HU, Emberton M
    An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, an
    Eur Urol. 2021 Jul 1. pii: S0302-2838(21)01817.
    PubMed     Abstract available


  201. BERGOUGNOUX A, Ea V, Paris F, Kalfa N, et al
    Reply to Zhongzhong Chen, Hua Xie, and Fang Chen's Letter to the Editor re: Vuthy Ea, Anne Bergougnoux, Pascal Philibert, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur U
    Eur Urol. 2021;80:e12-e13.
    PubMed    


  202. CHEN Z, Xie H, Chen F
    Re: Vuthy Ea, Anne Bergougnoux, Pascal Philibert, et al. How Far Should We Explore Hypospadias? Next-generation Sequencing Applied to a Large Cohort of Hypospadiac Patients. Eur Urol 2021;79:507-515.
    Eur Urol. 2021;80:e10-e11.
    PubMed    


    June 2021
  203. SATAPATHY S, Das N, Sood A, Goyal S, et al
    Short-course (177)Lu-PSMA-617 Radioligand Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer: Time to Take the Leap?
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01818.
    PubMed    


  204. SHARMA V, Karnes RJ
    Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
    Eur Urol. 2021 Jun 23. pii: S0302-2838(21)01806.
    PubMed    


  205. GLICKSMAN RM, Berlin A
    Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospect
    Eur Urol. 2021 Jun 19. pii: S0302-2838(21)01810.
    PubMed    


  206. CIMADAMORE A, Cheng L, Lopez-Beltran A, Scarpelli M, et al
    Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma o
    Eur Urol. 2021 Jun 17. pii: S0302-2838(21)01807.
    PubMed    


  207. WILKINSON S, Ye H, Lis RT, Sowalsky AG, et al
    Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance
    Eur Urol. 2021 Jun 17. pii: S0302-2838(21)01808.
    PubMed    


  208. GHADJAR P, Hayoz S, Bernhard J, Zwahlen DR, et al
    Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.
    Eur Urol. 2021 Jun 14. pii: S0302-2838(21)01802.
    PubMed     Abstract available


  209. TILKI D, Evans CP
    Re: Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.
    Eur Urol. 2021 Jun 9. pii: S0302-2838(21)01805.
    PubMed    


  210. SUMANASURIYA S, Seed G, Parr H, Christova R, et al
    Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    Eur Urol. 2021 Jun 5. pii: S0302-2838(21)01799.
    PubMed     Abstract available


  211. CHOW AK, Vourganti S, Konety BR
    Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.
    Eur Urol. 2021 Jun 3. pii: S0302-2838(21)01796.
    PubMed    


  212. CIMADAMORE A, Lopez-Beltran A, Scarpelli M, Montironi R, et al
    Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91.
    Eur Urol. 2021;79:e172-e173.
    PubMed    


  213. JONES TD, Cheng L
    Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Sys
    Eur Urol. 2021;79:e174-e175.
    PubMed    


  214. GUO C, Crespo M, Gurel B, Dolling D, et al
    CD38 in Advanced Prostate Cancers.
    Eur Urol. 2021;79:736-746.
    PubMed     Abstract available


  215. STOLZENBURG JU, Holze S, Neuhaus P, Kyriazis I, et al
    Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01).
    Eur Urol. 2021;79:750-759.
    PubMed     Abstract available


  216. EGAN J, Marhamati S, Carvalho FLF, Davis M, et al
    Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy: Single-surgeon Series and Step-by-
    Eur Urol. 2021;79:839-857.
    PubMed     Abstract available


    May 2021
  217. SATISH P, Simpson B, Freeman A, Giganti F, et al
    Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk.
    Eur Urol. 2021 May 28. pii: S0302-2838(21)00355.
    PubMed    


  218. LIAUW SL
    High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00392.
    PubMed    


  219. PADHANI AR, Rouviere O, Schoots IG
    Magnetic Resonance Imaging for Tailoring the Need to Biopsy During Follow-up for Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2021 May 27. pii: S0302-2838(21)00393.
    PubMed    


  220. SWEENEY CJ, Martin AJ, Stockler MR, Begbie S, et al
    Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
    Eur Urol. 2021 May 21. pii: S0302-2838(21)00354.
    PubMed     Abstract available


  221. XU J, Isaacs WB
    Incorporation of Polygenic Risk Score into Guidelines for Inherited Risk Assessment for Prostate Cancer.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00323.
    PubMed    


  222. RAJWA P, Pradere B, Quhal F, Mori K, et al
    Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
    Eur Urol. 2021 May 18. pii: S0302-2838(21)00325.
    PubMed     Abstract available


  223. PHILIPSON RG, Romero T, Wong JK, Stish BJ, et al
    Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
    Eur Urol. 2021 May 10. pii: S0302-2838(21)00314.
    PubMed     Abstract available


  224. CHENG HH
    Molecular Subtyping in the Neoadjuvant Setting in Prostate Cancer: Envisioning the Possibilities.
    Eur Urol. 2021 May 7. pii: S0302-2838(21)00308.
    PubMed    


  225. VAN POPPEL H, Hogenhout R, Albers P, van den Bergh RCN, et al
    Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European C
    Eur Urol. 2021 May 5. pii: S0302-2838(21)00297.
    PubMed    


  226. VAN DEN BROECK T, Oprea-Lager D, Moris L, Kailavasan M, et al
    A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.
    Eur Urol. 2021 May 4. pii: S0302-2838(21)00298.
    PubMed     Abstract available


  227. EVANGELISTA L, Lopci E
    Re: Hendrik Van Poppel, Renee Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327-9: Early Detection of Prostate Canc
    Eur Urol. 2021 May 1. pii: S0302-2838(21)00296.
    PubMed    


  228. DARST BF, Sheng X, Eeles RA, Kote-Jarai Z, et al
    Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.
    Eur Urol. 2021 May 1. pii: S0302-2838(21)00253.
    PubMed     Abstract available


  229. REITBLAT C, Bain PA, Porter ME, Bernstein DN, et al
    Value-Based Healthcare in Urology: A Collaborative Review.
    Eur Urol. 2021;79:571-585.
    PubMed     Abstract available


  230. SUNDAHL N, Gillessen S, Sweeney C, Ost P, et al
    When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities.
    Eur Urol. 2021;79:565-567.
    PubMed     Abstract available


    April 2021
  231. KIM SE, Shin JI, Shoag JE
    Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
    Eur Urol. 2021 Apr 30. pii: S0302-2838(21)00251.
    PubMed    


  232. VALLE LF, Kishan AU
    Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MAST
    Eur Urol. 2021 Apr 29. pii: S0302-2838(21)00250.
    PubMed    


  233. BERCHUCK JE, Zhang Z, Silver R, Kwak L, et al
    Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Eur Urol. 2021 Apr 19. pii: S0302-2838(21)00237.
    PubMed     Abstract available


  234. ADELEKE S, Haroon A, Kasivisvanathan V
    Re: [(177)Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial.
    Eur Urol. 2021 Apr 16. pii: S0302-2838(21)00245.
    PubMed    


  235. CHU CE, Alshalalfa M, Sjostrom M, Zhao SG, et al
    Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00215.
    PubMed     Abstract available


  236. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Eur Urol. 2021 Apr 8. pii: S0302-2838(21)00175.
    PubMed     Abstract available


  237. PIAZZA P, Rosiello G, Chacon VT, Puliatti S, et al
    Robot-assisted Cystectomy with Intracorporeal Urinary Diversion After Pelvic Irradiation for Prostate Cancer: Technique and Results from a Single High-volume Center.
    Eur Urol. 2021 Apr 7. pii: S0302-2838(21)00229.
    PubMed     Abstract available


  238. OKE O, Ranasinghe W, Tang C, Shaaban S, et al
    Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.
    Eur Urol. 2021 Apr 3. pii: S0302-2838(21)00228.
    PubMed    


  239. FICARRA V, Rossanese M, Crestani A, Alario G, et al
    Robot-assisted Radical Prostatectomy Using the Novel Urethral Fixation Technique Versus Standard Vesicourethral Anastomosis.
    Eur Urol. 2021;79:530-536.
    PubMed     Abstract available


  240. GIGANTI F, Kasivisvanathan V, Allen C, Moore CM, et al
    The Importance of Being PRECISE in Prostate Magnetic Resonance Imaging and Active Surveillance.
    Eur Urol. 2021;79:560-563.
    PubMed    


  241. HAMILTON RJ, Ding K, Crook JM, O'Callaghan CJ, et al
    The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.
    Eur Urol. 2021;79:446-452.
    PubMed     Abstract available


  242. KNIPPER S, Ascalone L, Ziegler B, Hohenhorst JL, et al
    Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy.
    Eur Urol. 2021;79:537-544.
    PubMed     Abstract available


  243. GIANNARINI G, Valotto C, Girometti R, Dal Moro F, et al
    Measuring the Quality of Diagnostic Prostate Magnetic Resonance Imaging: A Urologist's Perspective.
    Eur Urol. 2021;79:440-441.
    PubMed     Abstract available


    March 2021
  244. MOSCHOVAS MC, Bhat S, Sandri M, Rogers T, et al
    Comparing the Approach to Radical Prostatectomy Using the Multiport da Vinci Xi and da Vinci SP Robots: A Propensity Score Analysis of Perioperative Outcomes.
    Eur Urol. 2021;79:393-404.
    PubMed     Abstract available


  245. LENFANT L, Garisto J, Sawczyn G, Wilson CA, et al
    Robot-assisted Radical Prostatectomy Using Single-port Perineal Approach: Technique and Single-surgeon Matched-paired Comparative Outcomes.
    Eur Urol. 2021;79:384-392.
    PubMed     Abstract available


    February 2021
  246. ROSIELLO G, Piazza P, Tames V, Farinha R, et al
    The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00149.
    PubMed     Abstract available


  247. RANASINGHE W, Shapiro DD, Hwang H, Wang X, et al
    Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.
    Eur Urol. 2021;79:298-306.
    PubMed     Abstract available


  248. HU JC, Basourakos SP, Futterer J
    Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation.
    Eur Urol. 2021;79:167-169.
    PubMed     Abstract available


    January 2021
  249. VAN DIJK N, Gomez de Liano Lista A, Szabados B, Powles T, et al
    Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gomez de Liano Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-P
    Eur Urol. 2021;79:e20-e21.
    PubMed    


  250. KYPRIANOU N
    Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-cell Analysis.
    Eur Urol. 2021;79:161-162.
    PubMed    


  251. MORGANS AK
    Minimizing Risk to Maximize Outcomes.
    Eur Urol. 2021;79:54-55.
    PubMed    


  252. CHEN Y, Wang Z, Liu J
    Re: Giovanni Lavorgna, Riccardo Vago, Francesco Montorsi, Andrea Salonia. Surnames in Y-Chromosome-related Diseases: A New Tool for the Urologist? Eur Urol 2020;77:767-8.
    Eur Urol. 2021;79:e37.
    PubMed    


  253. DELL'OGLIO P, Meershoek P, Maurer T, Wit EMK, et al
    A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy.
    Eur Urol. 2021;79:124-132.
    PubMed     Abstract available


  254. STAVRINIDES V, Syer T, Hu Y, Giganti F, et al
    False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naive Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
    Eur Urol. 2021;79:20-29.
    PubMed     Abstract available


    November 2020
  255. IYER G, Bochner BH, Van Allen EM, Solit DB, et al
    Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30865.
    PubMed    


  256. BECKER REN, Baras A, Bivalacqua TJ
    Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicato
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30864.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: